面向家庭的心理治疗对遗传性血管管理的影响:一系列案例
Abyson Kalladanthyil1, Ami J Patel2, Rama R Gogineni3
1Psychiatry, Cooper Medical School of Rowan University, Camden, USA.
Cureus
|August 27, 2024
概括
以家庭为中心的心理治疗可以通过解决独特的家庭压力因素来帮助管理遗传性血管 (HAE). 这种方法有助于制定应对策略,以防止家庭内部情况恶化.
科学领域:
- 精神病学是一个精神病学.
- 遗传学 是一个遗传学.
- 家庭治疗 家庭治疗
背景情况:
- 心理治疗,特别是以家庭为导向的方法,是为慢性疾病管理而建立的.
- 重点是个人应对,思想,情感和行为改变.
- 益处包括减少症状,改善并发症 (焦虑,抑郁症) 和提高生活质量.
研究的目的:
- 研究以家庭为中心的心理治疗在治疗遗传性血管 (HAE) 的应用和有效性.
- 探索以家庭为中心的心理治疗如何解决家庭单位内与HAE相关的特定压力因素.
主要方法:
- 介绍了一个家庭的案例系列,该家庭因遗传性血管 (HAE) 接受了以家庭为中心的心理治疗.
- 专注于识别家庭压力因素,并制定适合HAE的应对策略.
主要成果:
- 该案例系列展示了以家庭为中心的心理治疗在HAE环境中的利用.
- 突出了以家庭为中心的心理治疗在管理遗传疾病方面的潜力.
结论:
- 以家庭为中心的心理治疗提供了一个有前途的模式,以解决受遗传性血管 (HAE) 影响的家庭复杂的心理社会需求.
- 需要进一步的研究来确定这种方法对遗传疾病的有效性.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
145
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
145
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149
Antiasthma Drugs: Leukotriene Modifiers
259
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
259
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
254
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
254
Open Angle Glaucoma: Treatment
413
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
413


